Honz Pharmaceutical Co., Ltd. (SHE:300086)
China · Delayed Price · Currency is CNY 6.11
-0.06 (-0.97%)
Jul 30, 2026, 3:04 PM CST
Honz Pharmaceutical Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 2,781 | 5,475 | 2,230 | 2,642 | 2,799 | 3,906 | |
Market Cap Growth | -23.63% | 145.51% | -15.57% | -5.63% | -28.34% | 54.45% |
Enterprise Value | 3,219 | 5,967 | 2,676 | 3,033 | 3,196 | 4,251 |
Last Close Price | 6.11 | 12.03 | 4.90 | 5.87 | 6.22 | 8.68 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | - | - | 229.10 | - | 355.50 |
Forward PE | - | 36.32 | 36.32 | 36.32 | 36.32 | 36.32 |
PS Ratio | 6.18 | 11.75 | 4.75 | 3.57 | 5.22 | 4.67 |
PB Ratio | 3.06 | 5.94 | 1.96 | 1.92 | 2.07 | 2.51 |
P/TBV Ratio | 3.40 | 6.62 | 2.32 | 2.27 | 2.48 | 3.05 |
P/FCF Ratio | 77.96 | 188.01 | - | - | - | - |
P/OCF Ratio | 48.11 | 45.16 | 31.21 | 37.37 | 95.45 | 344.77 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 7.15 | 12.80 | 5.70 | 4.10 | 5.97 | 5.08 |
EV/EBITDA Ratio | - | - | - | 22.93 | - | 126.48 |
EV/EBIT Ratio | - | - | - | 55.30 | - | - |
EV/FCF Ratio | 90.25 | 204.91 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.48 | 0.49 | 0.45 | 0.36 | 0.43 | 0.38 |
Debt / EBITDA Ratio | - | - | - | 3.79 | - | 15.09 |
Debt / FCF Ratio | 12.18 | 15.34 | - | - | - | - |
Net Debt / Equity Ratio | 0.46 | 0.42 | 0.35 | 0.26 | 0.23 | 0.22 |
Net Debt / EBITDA Ratio | -4.56 | -4.05 | -4.64 | 2.70 | -3.25 | 9.93 |
Net Debt / FCF Ratio | 11.70 | 13.29 | -18.89 | -5.33 | -10.58 | -1.60 |
Asset Turnover | 0.24 | 0.25 | 0.23 | 0.33 | 0.23 | 0.33 |
Inventory Turnover | 1.22 | 1.27 | 1.06 | 1.47 | 1.46 | 2.05 |
Quick Ratio | 0.13 | 0.19 | 0.40 | 0.85 | 0.79 | 0.99 |
Current Ratio | 0.50 | 0.52 | 0.85 | 1.60 | 1.33 | 1.49 |
Return on Equity (ROE) | -22.86% | -22.70% | -17.76% | 0.38% | -13.61% | 0.67% |
Return on Assets (ROA) | -5.27% | -5.36% | -4.49% | 1.54% | -3.86% | -0.13% |
Return on Invested Capital (ROIC) | -12.02% | -11.35% | -9.10% | 0.71% | -8.25% | -0.14% |
Return on Capital Employed (ROCE) | -13.20% | -13.40% | -10.20% | 3.10% | -8.20% | -0.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | -8.35% | -4.20% | -9.66% | 0.44% | -6.70% | 0.28% |
FCF Yield | 1.28% | 0.53% | -0.94% | -2.53% | -1.06% | -5.34% |
Payout Ratio | - | - | - | 211.14% | - | 370.22% |
Buyback Yield / Dilution | -0.59% | -0.84% | -0.20% | -0.10% | 0.08% | -0.29% |
Total Shareholder Return | -0.59% | -0.84% | -0.20% | -0.10% | 0.08% | -0.29% |